SERB Pharmaceuticals Announces ThyroSafe 130 mg Potassium Iodide Tablets are Now Commercially Available in the US

SERB Pharmaceuticals, a specialty pharmaceutical company focused on rare diseases and medical emergencies, has launched ThyroSafe 130 mg potassium iodide tablets in the US. The tablets provide an FDA-approved adult dose of potassium iodide in a single tablet, aligning with recommendations for individuals within a 10-mile nuclear Emergency Planning Zone. With 94 operating nuclear reactors in the US, the company emphasizes the importance of potassium iodide in emergency preparedness. ThyroSafe blocks or reduces the risk of radioactive iodine entering the thyroid gland following nuclear radiation exposure, which could cause delayed damage. The tablets feature a precision-scored design for accurate dosing, allowing adults to split them for pediatric use alongside the existing 65 mg formulation. This makes ThyroSafe suitable for family-focused preparedness. The product is available for purchase online without a prescription from retailers including Amazon, Walmart, and eBay. SERB Pharmaceuticals, which operates globally with a presence in the US, Europe, and the Middle East, has distributed emergency medicines in over 100 countries for more than 30 years. Potassium iodide should only be taken as directed by public officials during a nuclear radiation emergency, with each tablet offering 24 hours of protection. Authorities recommend daily use for 10–14 days until the risk of radioactive iodine exposure subsides. Overdosing does not enhance protection and may increase side effects. ThyroSafe is part of SERB’s portfolio of medical countermeasures for nuclear, biological, chemical, and radiological (CBRN) threats. The company’s mission includes improving emergency preparedness and public-sector readiness through specialized medicines.